Ertugliflozin + Sitagliptin

Generic Medicine Info
Indications and Dosage
Type 2 diabetes mellitus
Adult: Available preparations:
Ertugliflozin 5 mg and sitagliptin 100 mg tab
Ertugliflozin 15 mg and sitagliptin 100 mg tab

As an adjunct to diet and exercise to improve glycaemic control: Initially, 5 mg ertugliflozin/100 mg sitagliptin once daily, taken in the morning. Dose may be increased up to Max 15 mg ertugliflozin/100 mg sitagliptin once daily if further glycaemic control is needed. Patients already taking ertugliflozin: Maintain current ertugliflozin dose with sitagliptin 100 mg once daily. Correct volume depletion prior to treatment initiation, if present.
Renal Impairment
eGFR 45-<60 mL/min/1.73 m2: Not recommended; eGFR <45 mL/min/1.73 m2 and patients with ESRD or undergoing dialysis: Contraindicated.
Hepatic Impairment
Severe (Child-Pugh class C): Not recommended.
Renal impairment (eGFR <45 mL/min/1.73 m2); patients with ESRD or undergoing dialysis.
Special Precautions
Patient with volume depletion, CV disease; history of genital mycotic infections, pancreatitis, hypotension, or angioedema with other DPP-4 inhibitor; risk factors predisposing to ketoacidosis (e.g. pancreatic insulin deficiency, caloric restriction, alcohol abuse, acute febrile illness, dehydration, pancreatic surgery) or amputation (e.g. peripheral vascular disease, diabetic foot ulcers, neuropathy, prior amputation); risk factors for acute kidney injury (e.g. hypovolaemia, chronic renal insufficiency, CHF); undergoing surgery, including bariatric procedures. Uncircumcised males. Temporarily discontinue therapy ≥4 days before surgery or any event that may precipitate ketoacidosis. Not indicated for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis. Renal (eGFR 45-<60 mL/min/1.73 m2) and severe hepatic impairment. Elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Bone fractures, severe arthralgia, bullous pemphigoid, genital mycotic infections (e.g. candidal balanitis, balanoposthitis, vulvovaginitis, vulvovaginal candidiasis), symptomatic hypotension, volume depletion, lower limb amputation (mainly of the toe), acute renal injury or failure, impaired renal function (e.g. decreased eGFR, increased serum creatinine), serious UTIs (e.g. pyelonephritis, urosepsis), increased LDL-cholesterol (LDL-C), heart failure, hypoglycaemia.
Gastrointestinal disorders: Constipation, vomiting, stomatitis, diarrhoea.
Investigations: Increased Hb, BUN, hepatic enzymes; serum lipid changes, decreased weight.
Metabolism and nutrition disorders: Thirst.
Musculoskeletal and connective tissue disorders: Back pain, myalgia, rhabdomyolysis, pain in extremity.
Nervous system disorders: Headache, dizziness.
Renal and urinary disorders: Increased urination.
Reproductive system and breast disorders: Vulvovaginal pruritus.
Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection, nasopharyngitis.
Skin and subcutaneous tissue disorders: Pruritus.
Potentially Fatal: Acute pancreatitis including haemorrhagic or necrotising pancreatitis, serious hypersensitivity reactions (e.g. anaphylaxis, angioedema, Stevens-Johnson syndrome). Rarely, diabetic ketoacidosis, necrotising fasciitis of the perineum (Fournier’s gangrene).
Patient Counseling Information
This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery. This drug may also increase your risk of lower limb amputations; it is important to adhere to your routine preventive foot care.
Monitoring Parameters
Monitor blood glucose, HbA1c (at least twice yearly in patients with stable glycaemic control; quarterly in patients not meeting treatment goals), renal function (at baseline and periodically during therapy), volume status (e.g. blood pressure, electrolytes, haematocrit); LDL-C. Assess for signs or symptoms of acute pancreatitis, heart failure, genital mycotic infections, UTIs, hypersensitivity reactions; sores, ulcers, or infection of the lower limb and feet. Confirm signs of ketoacidosis by directly measuring blood ketones and arterial pH.
Drug Interactions
Ertugliflozin: Increased risk of hypoglycaemia when combined with insulin or insulin secretagogues (e.g. sulfonylurea). May increase the risk of hypotension and dehydration with diuretics.
Sitagliptin may cause a slight increase in plasma digoxin concentrations.
Lab Interference
Ertugliflozin: May cause positive test result for glucosuria. May interfere with glycaemic control monitoring using 1,5-anhydroglucitol (1,5-AG) assay.
Mechanism of Action: Ertugliflozin is a potent, selective, and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2), the main transporter responsible for filtered glucose reabsorption in the renal proximal convoluted tubules. Inhibition of SGLT2 reduces the renal reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion and reducing plasma glucose levels.
Sitagliptin inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme resulting in prolonged active incretin levels. Incretin hormones, including glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic β-cells and lowering glucagon secretion from pancreatic α-cells. Reduced glucagon secretion leads to decreased hepatic glucose production.
Absorption: Ertugliflozin: Bioavailability: Approx 100%. Time to peak plasma concentration: Approx 1 hour.
Sitagliptin: Rapidly absorbed from the gastrointestinal tract. Bioavailability: Approx 87%. Time to peak plasma concentration: Approx 1-4 hours.
Distribution: Ertugliflozin: Volume of distribution: 86 L. Plasma protein binding: Approx 94%.
Sitagliptin: Volume of distribution: Approx 198 L. Plasma protein binding: 38%.
Metabolism: Ertugliflozin: Extensively metabolised primarily by uridine diphosphate glucuronosyltransferases (UGT)1A9 and UGT2B7 via O-glucuronidation into 2 inactive metabolites; undergoes minimal metabolism by CYP450 isoenzyme.
Sitagliptin: Undergoes minimal metabolism, mainly by CYP3A4 isoenzyme and to a lesser extent by CYP2C8 isoenzyme.
Excretion: Ertugliflozin: Via urine (approx 50%; 1.5% as unchanged drug); faeces (approx 41%; approx 34% as unchanged drug). Elimination half-life: Approx 17 hours.
Sitagliptin: Via urine (approx 79% as unchanged drug; 16% as metabolites) and faeces (13%). Terminal half-life: Approx 12 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Ertugliflozin, CID=44814423, (accessed on Apr. 27, 2020)

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Sitagliptin, CID=4369359, (accessed on Jan. 22, 2020)

Store between 15-30°C. Protect from moisture.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BD24 - sitagliptin and ertugliflozin ; Belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.
Anon. Ertugliflozin and Sitagliptin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/05/2020.

Buckingham R (ed). Ertugliflozin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/05/2020.

Buckingham R (ed). Sitagliptin Phosphate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/05/2020.

Steglujan 5 mg/100 mg and 15mg/100 mg Film-Coated Tablets (Merck Sharp & Dohme B.V.). European Medicines Agency [online]. Accessed 05/05/2020.

Steglujan Tablet, Film-Coated (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. Accessed 05/05/2020.

Disclaimer: This information is independently developed by MIMS based on Ertugliflozin + Sitagliptin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Steglujan
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in